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Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer’s disease (AD) because
cholinergic deﬁcit is a consistent and early ﬁnding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia
gravishadeﬀectivelyproventhatAchEinhibitionwasareachabletherapeutictarget.Subsequentlytacrine,donepezil,rivastigmine,
and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase
inhibitors(ChEI)continuetobedeveloped.TheseincludenewerChEIs,naturallyderivedChEIs,hybrids,andsyntheticanalogues.
In this paper, we summarize the diﬀerent types of ChEIs in development and their respective mechanisms of actions. This
pharmacological approach continues to be active with many promising compounds.
1.Introduction
Acetylcholinesterase (AChE) has proven to be the most
viable therapeutic target for symptomatic improvement in
Alzheimer’s disease (AD) because cholinergic deﬁcit is a
consistent and early ﬁnding in AD. Inhibition of AChE was
considered to be achievable as a therapeutic target because
of proven eﬃcacy of inhibition of peripheral AChE as a
treatment for myasthenia gravis (MG) proving that the
approach was feasible. However, selective inhibition of the
central nervous system (CNS) AChE initially proved to be
daunting. Before tacrine, physostigmine, the classic AChE
inhibitor (AChEI) was investigated as a treatment for AD.
Physostigmine was subsequently abandoned because of poor
tolerability. Four drugs are currently available for AD treat-
ment:galantamine,rivastigmine,donepezil,andmemantine.
The ﬁrst three are AChE inhibitors and memantine is not.
There are two types of cholinesterase, AChE and butyryl-
cholinesterase (BuChE). AChE is found primarily in the
blood and neural synapses. BuChE is found primarily in the
liver.Thebiggestdiﬀerencebetweenthetwoisthesubstrates.
AChE hydrolyzes acetylcholine (ACh) more quickly, and
BuChE hydrolyzes butyrylcholine (BuCh) more quickly.
BuCh is a synthetic compound used to distinguish AChE
receptors from BuChE receptors. Many of the drugs that are
available for treatment of AD target both AChE and BuChE,
but some are more selective than others. In this paper, we
will be focusing on older acetyl cholinesterase inhibitors
(ChEIs), current ChEI, naturally derived ChEI, hybrid ChEI,
and synthetic analogues.
2. Older Cholinesterase Inhibitors
2.1. Physostigmine (Eserine). Physostigmine was the ﬁrst
ChEI investigated for the treatment of AD. It is isolated
from the seeds of Physostigma venenosum as a parasympath-
omimetic plant alkaloid. Although it is able to pass through
the blood-brain barrier (BBB), it has a short half-life and
a narrow therapeutic index. It also has many side eﬀects
suchasnausea,vomiting, headaches,diarrhea, and dizziness.
Physostigmine was in use for MG, glaucoma, and delayed
gastric emptying. However, the drug was not approved
and was abandoned for AD use due to the disadvantages
mentioned above. The newer drugs proved to be more
eﬀective with a lower side eﬀect proﬁle [1].
2.2. Tacrine. Tacrine was the ﬁrst drug approved for treat-
ment of AD in 1993 [2]. It is a potent inhibitor of both
AChE and BuChE. Tacrine was approved both because2 International Journal of Alzheimer’s Disease
of eﬃcacy on the ADAS-Cog and on the global measure
compared to placebo in phase II and phase III clinical trials
of AD subjects [3]. However, widespread use of tacrine was
limited as it was poorly tolerated as it caused a number of
side eﬀects including nausea, vomiting, dizziness, diarrhea,
seizures, and syncope. Also, administration and compliance
were challenging due to four times a day dosing regimen
because of a short half-life. In addition, patients who
used the drug required periodic blood monitoring due to
hepatotoxicity [4]. Eventually, tacrine was discontinued due
to the aforementioned liver toxicity which was thought to
be caused by the aﬃnity for BuChE [2]a n db e c a u s el e s s
toxic, better tolerated drugs with easier dosing schedule were
approved.
2.3. Donepezil. Donepezil was approved in 1996 for the
treatment of mild-to-moderate AD. A twelve-week double-
blind study was performed by Rogers et al. A total of 468
AD patients were separated into three groups: placebo, low
dose (5mg/day), and high dose (5mg/day for week 1 and
then 10mg/day thereafter). Improvements were seen as soon
as three weeks, and clinically signiﬁcant eﬀects were seen
at nine weeks. The side eﬀects were comparable with the
placebo for the most part. Patients who were on the high
dose occasionally experienced transient nausea, diarrhea,
and insomnia [5]. Donepezil is also thought to have an
additional mechanism of action other than just as a ChEI.
It is believed that donepezil does not act only at just the
neurotransmitter level but also at a molecular and cellular
level in nearly every stage involved with the pathogenesis
of AD. These include, but are not limited to, inducing a
neuroprotective isoform of AChE, blocking various aspects
of the excitotoxic cascade induced by glutamate, mitigating
the eﬀects of oxidative stress, and reducing the expression
of inﬂammatory cytokines [6]. Donepezil is approved for
use in mild, moderate, and severe AD but not for other
forms of dementia. It has shown some beneﬁt in mild
cognitive impairment [7, 8] but is not approved for this
indication. Recently, a higher dose of 23mg formulation
was approved for use in moderate-to-severe AD subjects.
In the US, generic donepezil is now available. Donepezil is
well absorbed with a relative oral bioavailability of 100%
and reaches peak plasma concentrations in 3 to 4 hours.
The elimination half-life of donepezil is about 70 hours and
is approximately 96% bound to human plasma proteins.
Donepezil is metabolized by CYP 450 isoenzymes 2D6 and
3A4 and undergoes glucuronidation.
2.4. Rivastigmine. Rivastigmine is a small molecule and has
easy BBB permeability. Rivastigmine also has BuChE and
AChE inhibitory properties. Rivastigmine was approved for
the treatment of mild-to-moderate AD in 2000 and has
since gained approval for Parkinson’s related dementias.
Corey-Bloom et al. conducted a trial with 699 patients with
AD ranging from mild-to-moderately severe. The patients
were split into three groups: a placebo group, a group on
1 – 4 m g / d a y ,a n dag r o u po n6 – 1 2 m g / d a yf o r2 6w e e k s .
Patients in the 6–12mg/day group demonstrated signiﬁcant
improvements in cognition (ADAS-cog 4.94 points), activ-
ities of daily living, global assessment of change, and the
Mini-Mental State Examination (MMSE) [9]. In capsular
form, rivastigmine has been frequently associated with side
eﬀects of nausea, vomiting, anorexia, and diarrhea. In
2007, rivastigmine was reformulated for delivery through a
transdermal patch. This has resulted in signiﬁcantly lower
GI side eﬀects compared to the oral capsule. It is suitable
to be converted to a patch delivery system because it is a
small molecule (<300 Da in size), and it is both lipophilic
and hydrophilic. It is minimally metabolized by CYP450
cytochrome system with weak binding to plasma proteins
(approximately 40%). The duration of anticholinesterase
activity in cerebrospinal ﬂuid is approximately 10 hours after
a6 - m go r a ld o s e .
2.5.Galantamine. Thetherapeuticactionofgalantaminehas
been reported to be mainly produced by its sensitizing action
on nAChRs rather than by general cholinergic enhancement
due to cholinesterase inhibition. Galantamine was approved
for the treatment of mild-to-moderate AD in February 2001.
The trial conducted by Tariot et al. in 2000 consisted of 978
patients randomized to galantamine or matching placebo for
ﬁve months. Administration of galantamine was associated
with a signiﬁcant improvement on the ADAS-cog score
with 3.3 points for the 16mg/day group and 3.6 points
for the group on 24mg/day when compared to placebo.
Discontinuation of treatment due to adverse eﬀects was
minimalinbothgroupsandequaltotheplacebogroup.Both
of the treatment groups showed signiﬁcant improvement
in the behavioral, cognitive, and functional symptoms of
AD. Having a slow escalation of the dosage increased the
tolerability of the drug [10]. Absorption of galantamine is
rapid and complete and shows linear pharmacokinetics. It is
well absorbed with absolute oral bioavailability between 80
and 100%. It has a half-life of seven hours. Peak eﬀect of
inhibiting acetylcholinesterase was achieved about one hour
after a single oral dose of 8mg in some healthy volunteers.
Plasma protein binding of galantamine is about 18%.
2.6. Metrifonate. Metrifonate is a long-acting irreversible
ChEI that was originally used to treat schistosomiasis.
Although there was a low risk of side eﬀects with short-
term use, long-term use caused respiratory paralysis and
neuromuscular transmission dysfunction similar to a myas-
theniccrisis.Assuch,theFDAsubmissionwashaltedandthe
clinical trials were discontinued during phase III. However,
it did demonstrate a robust therapeutic eﬀect on ADAS-cog
and other measures. But, until the relationship between met-
rifonate and neuromuscular dysfunction is further explored,
metrifonate is not an option for AD treatment at this time
[11].MetrifonateisnotanapprovedADtreatmentbutshows
eﬃcacy that was outweighed by safety risks.
2.7. Older ChEIs Summary. Dozens of short-term clinical
trials, open-label extension studies, and long-term clinical
cohort observational studies generally point to the fol-
lowing (a) current ChEIs (donepezil, rivastigmine, andInternational Journal of Alzheimer’s Disease 3
galantamine) reduce cognitive, functional, and behavioral
decline in AD, (b) their eﬃcacies appear similar (there is no
level 1 grade data that shows otherwise), (c) their beneﬁts
are sustained with treatment persistence, (d) their beneﬁts
aregenerallydose-related(untillimitedbyside-eﬀectsatvery
highdoses),and(e)theyappeartoberelativelysafeandwell-
tolerated (see Table 1).
3. New Cholinesterase Inhibitors
3.1. Physostigmine Derivatives
3.1.1.Phenserine. Phenserineisthephenylcarbamatederiva-
tion of physostigmine that has a dual eﬀect: decreasing
beta-amyloid precursor protein and has a reversible AChE
inhibition. It has a quick absorption rate and is less toxic
than physostigmine and tacrine. It has also shown improved
learning and memory in aging rats and dogs. Another study
involving dogs showed that phenserine improved learning
and memory compared to dogs receiving placebo group [1].
Phase III clinical trials were conducted during 2003-2004
in which 384 AD patients recruited. The trials were con-
ducted using 10mg and 15mg twice daily doses. However,
phenserine did not achieve signiﬁcant improvement on the
ADAS-cogscorescomparedtoplacebo.Subsequently,further
clinical trials for AD have been abandoned [1]. Post hoc
analysis of all three Phase III clinical trials identiﬁed that the
group of subjects receiving the highest tested dose (15mg
per day) for more than 12 weeks demonstrated a statistically
signiﬁcant beneﬁt of phenserine over placebo in ADAS-
cog, but only a trend toward improvement in the CIBIC+
measure.
3.1.2. Tolserine. Tolserine only diﬀers from phenserine at
the 2 -methyl substitution on its phenylcarbamoyl moiety.
Preclinical studies wereinitiated in2000, and itwasshownto
be 200-fold more selective against hAChE versus BuChE [1].
Tolserine proved to be a highly potent inhibitor of human
AChE compared to its structural analogues physostigmine
and phenserine. However, there are no published reports on
Tolserineinhumanssoitisdiﬃculttoidentifypotentialrisks
and beneﬁts in preclinical or clinical models.
3.1.3. Esolerine. Zhan et al. conducted a study in which
a series of physostigmine analogues were prepared and
assessed for ChEI. Compound 17, a cyclic alkyl carbamate
of esolerine, a very strong AChE inhibitor and signiﬁcantly
favored AChE over BuChE [12]. Esolerine is a tacrine
derivative, but there are no published reports in humans
so it is diﬃcult to identify potential risks and beneﬁts in
preclinical and clinical models.
3.2. NS2330 (Tesofensine). Both in vitro and in vivo studies
have shown that tesofensine inhibits the presynaptic uptake
of the neurotransmitters serotonin, norepinephrine, and
dopamine.Thecompoundenhancesthefunctionoftheneu-
rotransmitters acetylcholine, noradrenaline, and dopamine,
which are all impaired in Alzheimer’s patients. A decrease in
beta-amyloid concentration was found in mice after use of
tesofensine which was thought to be a neuroprotective eﬀect.
Phase IIA trials showed signiﬁcant cognitive improvement
in those with mild AD. However, Phase IIB trials showed
limited activity. The trials were discontinued in 2008.
Currently, tesofensine is being marketed as a drug against
obesity [13, 14].
4. NaturallyDerived
4.1. Huperzine A. Huperzine A (HupA) is a Lycopodium
alkaloid isolated from the Chinese medicinal herb Huperzia
serrata used for memory deﬁciency. Huperzia serrata is
widely grown in China and Chinese medical tradition
emphasize herbal remedies. It has attracted much attention
because it is a highly selective, reversible, and potent AChE
inhibitor [15]. The synthetic racemic mixture of HupA has
less AChE inhibitory eﬀects than the natural kind. Many of
the initial derivates demonstrated lower potency than the
natural HupA. HupA has also been hybridized with tacrine
and donepezil. While the donepezil hybrid proved to be less
eﬀective, the HupA-tacrine hybrids called huprines Y and
X have shown to be more eﬀective in amplifying AChE in
vitro than tacrine. Huprines Y and Z were shown to have
better inhibitory activity than either of the parent drugs as
well [1]. HupA has a higher oral bioavailability compared to
tacrine and donepezil. The improvement is more noticeable
on working memory than reference memory as compared to
tacrine and donepezil as well [16]. HupA is also shown to be
more potent than tacrine, rivastigmine, and galantamine in
terms of inhibition activities, and it had the least amount of
activity against BuChE [15].
HupA is considered to be the drug of choice in China
for the treatment of memory disorders. It is also in Phase
II clinical trials in Europe [16]. Phase II trials have also
been conducted in over 30 sites in the US. A trial using a
lower dose of 200mcg twice daily showed no improvement
on the ADAS-cog scores, but a diﬀerent trial using a higher
dose of 400mcg twice daily showed statistically signiﬁcant
improvement in the ADAS-cog scores compared to placebo
[15, 17] with GI side eﬀects reported. Since it is marketed
in the US as a nutraceutical supplement because it lacks a
proprietary patent for the treatment of AD, FDA approval
is not being pursued. It is widely available as a supplement
marketed to enhance memory but with no labeling to treat
speciﬁc diseases.
4.2. Huperzine B. Natural Huperzine B (HupB) is a
Lycopodium alkaloid isolated from the Chinese medicinal
herb Huperzia serrata which has been demonstrated as an
eﬀective and reversible inhibitor of AChE. HupB is less
potentandselectivethanHupA,butithashighertherapeutic
index and other positive beneﬁts. HupB derivatives were
created to be more potent than natural HupB. A novel series
of 16-substituted derivatives were synthesized. 9i has the
highest potency in vitro. The eﬃcacy of 9i was more potent
in vitro than HupA, galantamine, and rivastigmine, and it
was equivalent to donepezil. 9c and 9i showed moderate4 International Journal of Alzheimer’s Disease
Table 1: Summary of ChEIs in preclinical and clinical development.
Drug Disposition
Physostigmine First drug investigated; however, it is no longer used due to side eﬀects, short half-life, and better treatment options.
Donepezil Highly selective AChEI. Approved for mild, moderate, and severe AD.
Rivastigmine H a sd u a lb C h E Ia n dA C h E Ip r o p e r t i e s .Approved for mild-to-moderate AD. Patch formulation has reduced
cholinergic-related side eﬀects.
Galantamine A lower potency AChEI with allosteric nicotinic receptor modulation properties.
Metrifonate A highly selective AChEI that demonstrated a robust and signiﬁcant clinical eﬀect, but was abandoned after Phase III
RCTs because of risk of neuromuscular dysfunction.
Phenserine A derivative of physostigmine with a dual mechanism of action including anti-Aβ properties as well as AChEI.
Despite a good safety proﬁle, it did not achieve signiﬁcant eﬃcacy during Phase II trials.
Tolserine A physostigmine derivative, has shown promise in the preclinical stages.
Esolerine Another physostigmine derivative, is also a strong AChEI and favors AChE over BuChE greatly. It has not entered
clinical trials.
NS2330
(tesofensine)
Robust preclinical eﬃcacy and safety data. Early Phase II studies showed a positive signal on cognition. Follow-up
RCTs for AD were discontinued in 2008 because of lack of clinical eﬃcacy signal. It is currently being investigated as a
treatment for obesity treatment.
Huperzine A HupA is natural herb that is marketed as a supplement in the US. It acts as a ChEI. It is drug of choice for AD in
China. Phase II trials in the US showed a modest but clinical signiﬁcant eﬀect on cognition in AD.
Huperzine B HupB is less potent and selective than HupA, but it has a higher therapeutic index.
Nelumbo
nucifera
The stamens of Nelumbo nucifera has demonstrated an improvement in memory in rats and favors AChE over
BuChE.
Himatanthus
lancifolius
A shrub with multiple medicinal purposes. The uliene in Himatanthus lancifolius is what is likely responsible for the
signiﬁcant AChE inhibitory eﬀects.
Galangin Galangin is a ﬂavonoid that demonstrated signiﬁcant inhibition of AChE. It has not been tested in human trials.
Donepezil
hybrids
(1) Of the series of hybrids derived from Donepezil and AP2238, compounds 15, 21, and 22 demonstrated the most
potential. Human studies have not been undertaken yet.
(2) The entire series of donepezil-tacrine hybrids showed more signiﬁcant beneﬁts than either parent drug alone.
Human studies are planned.
Tacrine hybrids
(1) The beta-carboline derivatives (2A, 2B, 2C) and tacrine/ferulic acid hybrids (1A, 1B) were shown to have no
eﬃcacy in vivo, and 1B actually worsened the impairment in an scopolamine-induced in vivo model. Clinical
development has not been pursued further.
(2) The tacrine-8-hdroxyquinoline hybrids showed potential in vitro,b u tt h ee ﬀects have yet to be shown in vivo.
Synthetic
analogues
(1) The majority of the phenyl-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenylmethanone analogues demonstrated
signiﬁcant AChEI in in vitro and in vivo models.
(2) N-alkyl-7-methoxytacrine hydrochlorides are also an area of interest as compounds 5–7 have more eﬃcacy than
THA and 7-MEOTA.
neuroprotection against H2O2-induced neurotoxicity [18].
However, given the ubiquitous availability of HupA and
its higher potency, clinical development of HupB has been
reportedly limited. Side eﬀects would be expected to be
similar in nature (GI) to HupA and other ChEIs.
4.3. Nelumbo nucifera. Nelumbo nucifera is an aquatic plant
with numerous medicinal properties. It has recently demon-
strated that the stamens fed to rats performing maze
learning tasks improved memory. The MOA is felt to be
AChE inhibition. One new compound and four known
compounds were isolated from the n-butanol fraction of
the N. nucifera for the ﬁrst time. The new compound is a
beta-cyclogeraniol diglycoside, nuciferoside (5), and the four
known compounds are cycloartenol (1), p-hydroxybenzoic
acid (2), vanilloloside (3), and 5 -O-methyladenosine (4).
Compounds 5 and 1–3 demonstrated good and noncompet-
itive AChE inhibition and compounds 1, 2, and 5 showed
exhibited BuChE inhibition. Compounds 1–3 and 5 have
possible ChE inhibitory eﬀects with the potential to be used
for AD treatment. The primary eﬀect would be as an AChE
inhibitor rather than as BACE1 inhibitors [19]. There are no
reports of human studies. Preclinical and clinical safety and
toxicity data are not reported.
4.4. Himatanthus lancifolius. Himatanthus lancifolius is a
shrub that contains several indole alkaloids with a number
of medicinal properties such as antimicrobial eﬀects, gas-
troprotection, and the ability to aﬀect the vascular and
nonvascular smooth muscle responsiveness. Seidl et al.
[20] conducted a study to determine if there were any
AChE inhibiting properties from the Himatanthus lancifolius
extract and uliene in vitro. The dichloromethane (DCM),
andethylacetate(EtOAc),fractionsshowedsigniﬁcantAChE
inhibitory eﬀects. Uliene was the signiﬁcant compound
presentinbothfractions[20].TherearenoreportsofhumanInternational Journal of Alzheimer’s Disease 5
studies speciﬁc to cognition. Preclinical and clinical safety
and toxicity data are not reported.
4.5. Galangin. Guo et al. studied 21 diﬀerent ﬂavonoids for
potential AChE inhibition properties in the brain in vitro.
Flavonoids have been of great interest in AD research and
treatment because of their free radical scavenging properties.
Epidemiological evidence suggests that higher consumption
of ﬂavonoids is associated with lower incidences of AD.
A ﬂavonol isolated from Rhizoma Alpiniae Oﬃcinarum
called galangin demonstrated the highest inhibitory eﬀects
on AChE activity. However, it is unknown if the galangin
binds to the AChE directly or has the same binding site
as the ATCh substrate [21]. Nevertheless, this suggests that
galangin could be developed as a potential treatment for AD
becauseof the dual MOA of ChEI and free radical scavenging
properties. There are no human studies reported to date.
Clinical and preclinical toxicities have not been established.
4.6. Cardanol Derivatives. de Paula et al. designed new
AChEI from nonisoprenoid phenolic lipids (NIPLs) of Anac-
ardium occidentale. Cardols, cardanols, anacardic acids, and
methylcardols are the primary NIPL components of cashew
nut-shell liquid (CNSL) and have been used to generate
potential bioactive compounds. The derivates have struc-
tural, electrical, and hydrophobic properties that are relevant
to recognition of AChE molecules. The study concluded
that the most promising candidates to the development
of AChEI for AD treatment were derived from cardanol
[22]. Development of cardanol is appealing because of the
abundancy of the raw material source. There are no human
studies reported to date. Clinical and preclinical toxicities
have not been established.
5. Hybrids
Since AD is a multifactorial disease, the innovative model is
of the “one molecule, multiple targets” approach. Hybrids
combine BBB permeability with drugs targeting multiple
receptors or epitopes. Further, hybrids oﬀer the promise of
dual MOAs and added potency. The multipotent approach
includes novel tacrine-melatonin hybrids, dual inhibitors
of AChE and MAO or serotonin transporters, potent
cholinesterase inhibitors with antioxidant and neuropro-
tective properties, gallamine-tacrine hybrids binding at
cholinesterases and M2 muscarinic receptors, NO-donor,
tacrine hybrids as hepatoprotective drugs focusing on AD or
ﬂuorescent tacrine, coumarin hybrids [23] .T h es i d ee ﬀects
proﬁles are unknown in humans at present.
5.1. 5-(N-Methyl-N-propargyl-aminomethyl) Quinolin-8-yl
Dimethyl Carbamate (2) and 5-(N-Methyl-N-propargylam-
inomethyl) Quinolin-8-yl Ethylmethyl Carbamate (3). One
type of new drug is a site-activated chelator that inhibits
both AChE and MAO A/B. Although the original chelators
(clioquinol and desferrioxamine) had success in clinical
trials, the drugs did not selectively target the biometals in
the brain. Therefore, the therapeutic use was limited due to
toxicity (in the case of clioquinol) or poor selectivity and
permeability. Now, chelators are designed with MAO A/B
inhibitory activity to enhance eﬃcacy and as prodrugs to
enhance targeting. This new prochelator would act as HLA
20A in that it would selectively inhibit AChE with minimal
metal ion binding aﬃnity, possess increased activity against
MAO A/B, and it would be activated by AChE, which is
located primarily in the brain, to release the active chelator
M30. The two compounds synthesized are compounds 2
and 3. Compounds 2 and 3 are like rivastigmine in that
the AChE inhibited progressively increases as incubation
time increases. Compound 2 is more potent and 3 is
less potent than rivastigmine in blocking AChE at 1μM.
Both compounds are more potent at inhibiting MAO-A
than M30, but compound 2 is less potent than M30 at
inhibiting MAO-B and compound 3 has minimal inhibitory
eﬀects. The biggest novelty is that M30 is combined with
these compounds into prochelators. Compound 2 is more
promising of the two [24].
5.2. Donepezil and AP2238. AP2238 is the ﬁrst published
compound to bind both anionic sites of AChE. The potency
against AChE is comparable to donepezil, while its ability
to contrast beta-amyloid aggregation is higher. Rizzo et al.
reports on a series of hybrids developed from donepezil and
AP2238 in which the idanone core from donepezil is linked
tothephenyl-N-methylbenzylaminomoietyfromAP2238.A
derivate in which the phenyl-N-methylbenzylamino moiety
from AP2238 was replaced by phenyl-N-ethylbenzylamino
moiety from AP2243 and the idanone ring was replaced
by a tetralone scaﬀold. A total of 22 compounds were
synthesized. Derivates 21 and 22 were the most active of
all the compounds, and the potency was equal to the
reference compounds. Compounds 15, 21, and 22 had a
5-carbon alkyl chain with an amino moiety at one end
which gave the compounds better contact at the peripheral
anionic site (PAS). This improved the inhibition of AChE-
induced aggregation vastly when compared to the reference
compounds. Compound 21 was a part of the tetralone series,
and the methoxy substituent in position 6 was replaced by
a pentyl chain. Compound 22 was a piperidine derivative
of the tetralone series. In compound 15, the second amino
moiety was replaced by piperidine with n = 5. Overall,
compounds 15, 21, and 22 showed the most promise [25].
There are no reports of human studies. Preclinical and
clinical safety and toxicity have not been established.
5.3. Donepezil-Tacrine Hybrids. Camps et al. designed a
novel series of donepezil-tacrine hybrids, which interact si-
multaneouslyattheperipheral,active,andmidgorgebinding
sites of AChE. They are desirable because both compounds
have known eﬃcacy and BBB permeability with slightly
diﬀerent MOAs. They were tested for the ability to inhibit
BuChE, AChE, and beta-amyloid aggregation induced by
AChE. The compounds are combination of the 5,6-dime-
thoxy-2-[(4-piperidinyl)methyl]-1-idanone moiety of done-
pezil and 6-chlorotacrine. All of the new hybrids have
proven to be highly potent hAChE inhibitors. All of the new6 International Journal of Alzheimer’s Disease
compoundsalsodemonstratedsigniﬁcantinhibition ofbeta-
amyloid aggregation and were shown to be more potent than
parent compounds [26].
5.4. Tacrine/Ferulic Acid Hybrids and Beta-Carboline Deriva-
tives. Three beta-carboline derivatives (referred to as with-
out chemical names (2A, 2B, 2C)) and two tacrine/ferulic
acid hybrids (1A, 1B) were tested in vivo in three-month-
old female rats. The tacrine/ferulic acid hybrids showed
higher AChE inhibition and comparable BuChE inhibition
when compared to tacrine in vitro. However, neither com-
pounds 1A nor 1B showed any therapeutic eﬀects against
scopolamine-induced cognitive deﬁcits in vivo.C o m p o u n d
1B actually worsened the impairment. Compound 2C was
shown to be the most eﬀective of the three in vitro.
Compound 2B did not show any signiﬁcant activity, and
compound 2A was comparable to galantamine. However,
none of these three compounds were shown to be eﬀective
in vivo. Despite the promising in vitro information, none of
the ﬁve compounds are suitable for AChE inhibition against
AD [27].
5.5. Tacrine-8-hydroxyquinoline Hybrids. Both tacrine and
PBT2 (an 8-hydroxyquinoline derivative) are known for
ChE inhibition and decreasing beta-amyloid concentrations,
respectively.Fernandez-Bachilleretal.designed,synthesized,
and evaluated novel tacrine-8-hdroxyquinoline hybrids as
possible therapeutic drugs for AD treatment. The hybrids
w e r ef o u n dt ob em o r ee ﬀective than tacrine against AChE
and BuChE. They also show low cell level toxicity and
could possibly penetrate the CNS as demonstrated by an in
vitro BBB. The drug has also demonstrated antioxidant and
copper-complexing properties. With all the properties that
these hybrids possess, it could be a possible therapeutic drug
treatment in vivo as well [3].
5.6. Other Hybrids Combinations. Samadi et al. studied
tacripyrines and developed a new compound called p-
methoxytacripyrine (RL2/101). RL2/101 impedes the proag-
gregation beta-amyloid eﬀect of hAChE and has mild
inhibitory eﬀects on the self-aggregation of Aβ 42. RL2/101
is a potent Ca2+ antagonist that passes through the
blood-brain barrier (BBB). It also displays antioxidant and
neuroprotective properties. Samadi et al. carried out with
the synthesis of a number of series of simple, and read-
ily available 2-aminopyridine-3,5-dicarbonitriles (3–22),
and 2-chloropyridine-3,5-dicarbonitriles (21–28) derived
from 2-amino-6-chloropyridine-3,5-dicarbonitrile (1) and
2-amino-6-chloro-4-phenylpyridine-3,5-dicarbonitrile (2).
Compounds 3, 4, 21–23, 25, 26 were shown to be highly
selective for hAChE. Compounds bearing small groups such
astheN,N0-dimethylamino orthepyrrolidino preferentially
inhibit AChE. Compounds 3, 17, 22, 24, and 26 showed
the highest neuroprotection values. These compounds could
be further developed to have multifaceted approach against
cholinergic dysfunction and oxidative stress [23].
Camps et al. designed two new series of hybrid AChEIs
and tested them for AChE inhibition, butyrylcholinesterase,
BACE-1, and self-induced and AChE-induced beta-amyloid
aggregation and BBB permeability. The hybrids are com-
posed of a 6-unit chlorotacrine and a multicomponent
reaction-derived pyrano [3,2-c]-quinoline scaﬀold as the
active and peripheral sites interacting moieties, respectively.
Due to the dual binding site activity, both hybrids demon-
strate the ability to inhibit AChE-induced beta-amyloid1−40
aggregation and self-induced beta-amyloid1−42 aggregation.
Some of compounds can also inhibit BACE-1. These hybrids
alsohavetheabilitytopermeatetheBBB.Hybrid27emerged
asthemostpromisingtherapeuticasitwasabletotargetboth
AChE and beta-amyloid production and aggregation [28].
6.SyntheticAnalogues
6.1. Phenyl-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenyl-
methanone Analogues. Synthetic analogues are under devel-
opment because, with targeted pharmacological develop-
ment, class-speciﬁc hepatotoxicity and known gastrointesti-
nal side eﬀects may be avoided. The risk of developing
synthetic analogs is that they might not have the potency
and BBB permeability as naturally derived ChEIs or they
may have unanticipated pharmacological properties. Ali
et al. synthesized phenyl-5,6-dimethoxy-1-oxo-2,3-dihydro-
1H-2-indenylmethanone analogues labeled 5a–5n.T h e i r
data showed that the majority of the compounds had mod-
erate AChE inhibitory eﬀects. 5f had the most signiﬁcant
eﬀects followed by 5e and then 5a. The study suggests that
having an OCH3 group substituted phenyl ring at diketone
derivatives creates a vast improvement in AChE inhibition
[29].
6.2. N-Alkyl-7-methoxytacrine Hydrochlorides. The ﬁrst
AChEI developed was THA, but using the drug caused dose-
dependent but reversible liver toxicity. 7-methoxytacrine
(7-MEOTA) is an analogue of THA that has far less
toxicity and is pharmacologically equivalent to THA. In a
study by Korabecny, fourteen 7-MEOTA analogues were
synthesized. Models of human recombinant AChE (hAChE)
and human plasmatic BuChE (hBuChE) were used to
evaluate these new analogues in vitro and were compared
to THA and 7-MEOTA. Compounds 5–7 showed better
inhibition of hAChE than compared to 7-MEOTA and THA,
especially compound 5 as it was found to be ﬁve times
more potent than THA. Compounds 9, 10, and 14 were
found to be ineﬀective against hAChE. The structure-activity
relationship ﬁndings point at the C6-C7 N-alkyl chains for
cholinesterase inhibition [30].
6.3. Ladostigil. Ladostigil is a novel anti-Alzheimer’s dis-
ease drug, with neuroprotective, multimodal brain-selective
monoamine oxidase, and cholinesterase inhibitor properties
[31]. It has neuroprotective and antioxidant activities in
cellular models at much lower concentrations than those
inhibitingMAOorAChE.Whenladostigil(1mg/kg/day)was
given for 6 months to 16-month-old rats, it prevented the
age-related increase in activated astrocytes and microglia in
several hippocampal and white matter regions and increasedInternational Journal of Alzheimer’s Disease 7
proNGF immunoreactivity in the hippocampus towards the
levels in young rats.
Ladostigil also prevented the age-related reduction in
cortical AChE activity and the increase in butyrylcholin-
esterase activity in the hippocampus, in association with
the reduction in gliosis. The immunological and enzymatic
changes in aged rats were associated with improved spatial
memory. Ladostigil treatment had no eﬀect on memory,
glial, or proNGF immunoreactivity in young rats [32].
Ladostigil ((N-propargyl-(3R) aminoindan-5yl)-ethyl meth-
yl carbamate) is, presently in a Phase IIb clinical trial
and intended for the treatment of Alzheimer’s disease and
dementia comorbid with extrapyramidal disorders and de-
pression [31].
7. Discussion
A great deal of research has been done regarding AChEI
as a therapeutic drug for AD. All of the current ﬁrst-
line treatments in the US are AChEIs. Physostigmine was
the ﬁrst ChEI investigated for AD, but it was discarded
due to a number of disadvantages. Although phenserine,
a physostigmine derivative, has failed the Phase II clinical
trials,thereareotherderivativesindevelopment.Inaddition,
metrifonate also has a profound eﬀect on those with AD. A
metrifonate derivative with the same or better eﬃcacy and
a lesser side eﬀect proﬁle would be a promising therapeutic
drug. Naturally derived AChEIs are also a promising area of
interest. HupA is the drug of choice in China [16]. Many
hybrids are also being created. Some hybrids have completely
new materials, but other hybrids are using the older AChEI
and are trying to improve upon them. The synthetic
analogues have only been tested in vitro at this time, but it is
an area that can help direct future treatment options for AD.
Although the majority of the drugs discussed in this paper
have not yet been tested in animals or humans, each of these
areas will continue to develop because this class of drugs
has demonstrated its value in symptomatic therapy. This
class of drugs will continue to be developed because it is a
proven symptomatic therapy with a recognized target. Drugs
in the class have a proven track of CNS permeability, known
side eﬀe c tp r o ﬁ l e ,a n dd e m o n s t r a t e de ﬃcacy. It is logical to
consider further development of novel agents in this class.
Challenges to development include potency, safety, and side
eﬀectsaswellascomparisontocurrentChEIs,manyofwhich
are generic. Many compounds developed to date have no
human or animal data. Thus, safety, eﬃcacy, and toxicity
have not been established. Further, this class of medications
has not been established to possess disease-modifying prop-
erties. The risk of developing newer ChEIs is that they will
need to be more eﬀective than donepezil, rivastigmine, and
galantamine to garner approval since these three drugs are
FDAapproved.Futureresearchinthisclasswillneedtofocus
on whether ChEIs directly aﬀect the pathophysiology of AD.
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